Acadia About
Acadia: ACP-103
for treatment-induced dysfunction in Parkinson's
disease ACP-103
as an adjunctive therapy for Schizophrenia
ACP-104 for treatment of Schizophrenia.
ACADIA also
has clinical and preclinical development programs in the areas of neuropathic
pain and glaucoma (in collaboration with Allergan, Inc.)
ACADIA is developing
ACP-103, a potent and selective 5-HT2Ainverse agonist, as an adjunctive therapy
for schizophrenia. By adding ACP-103 in combination with currently-available antipsychotic
drugs they believe that the optimal combination of dopamine receptor blockade
and 5-HT2Ainverse agonism can be achieved, which may reduce the side effects associated
with these drugs and expand their range of efficacy. ACP-103
in Clinical Development A
proprietary small molecule discovered by ACADIA, is in development for treatment
of the psychiatric and motoric dysfunction that frequently results from current
Parkinson's disease therapies. ACP-103 is given orally and blocks the activity
of the 5-HT2A receptor. Neuropathic
Pain
In collaboration with Allergan, ACADIA is developing a new class of small
molecule drug candidates that they believe may represent a significant breakthrough
in the treatment of neuropathic pain read
more.
Key
Statistics for Acadia
ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical
company utilizing innovative technology to fuel drug discovery and clinical development
of novel treatments for central nervous system disorders including
Schizophrenia and Parkinson's disease. ACADIA currently has five drug programs
in clinical and preclinical development. Their three Phase II-stage clinical programs,
for which we they have retained worldwide commercialization rights
are:
Drug
Programs
ACP-103 as Adjunctive Therapy for Schizophrenia
NIH
Clinical Trials:
Hallucinations
Psychoses Parkinson's Disease Colorectal
Cancer Metastases NIH
Link
More on Acadia:
Basic
Chart for Acadia
Analyst
Opinion
Analysts
Estimates